{"Clinical Trial ID": "NCT00558103", "Intervention": ["INTERVENTION 1:", "Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo", "Participants received an oral lapatinib of 1500 milligrams (mg) (6 250 mg tablets) in combination with placebo (pazopanib pairing; 2 tablets) once daily (QD).", "INTERVENTION 2:", "Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg", "Participants received oral lapatinib 1500 mg (6 250 mg tablets) in combination with pazopanib 800 mg (2 400 mg tablets) QD."], "Eligibility": ["\u2022 Inclusion criteria:", "Specific information regarding warnings, precautions, contraindications, adverse events and other relevant information on the trial product that may affect patient eligibility is provided in the information prescribed by pazopanib IB and lapatinib (or lapatinib IB).", "For cohort 1 of this study, eligible patients met the inclusion criteria set out in the original protocol and protocol 1 amendment.", "For cohort 2 of this study, eligible patients must meet all of the following criteria:", "Patients should have evaluable inflammatory breast cancer (IBC) supported by all of the following prior to randomization:", "\u2022 History of invasive breast cancer documented by a biopsy and related pathology report", "Current photographs* (comprehensive view and close view of all skin lesions) presented during screening demonstrating unequivocal evidence of CWB as determined either by the medical supervisor alone or in consultation with one or more of the study's principal investigators.", "Canfield Scientific Inc. will provide centralized surveillance, follow-up and collection of patient photographs throughout the study. Screening photographs must be downloaded from the Canfield Scientific Inc. website and approved by Canfield Scientific Inc. as the central provider of photographs. Photographs, as well as the Inflammatory Breast Cancer Skin Assessment Tool (IBSAT), must be reviewed and approved by GSK before a patient can be randomized. The sites should provide a minimum of 3 business days for this process.", "Patients with secondary IBCs are eligible.", "If the irradiated injury is the only site of the disease, a documented progression of the irradiated injury is required.", "In regions where trastuzumab is available without barriers to access*, patients must have received trastuzumab in addition to chemotherapy to be eligible. * (Access barriers may include financial considerations.)", "The amplification of the ErbB2 gene is defined by: > six (6) copies/core of the ErbB2 gene for test systems without an internal control probe or with an ErbB2/CEP 17 ratio greater than 2.2.", "The sites must submit a copy of the laboratory report demonstrating an unequivocal ErbB2 overexpression, if the tests are carried out in a local laboratory, with the screening worksheet. The archived tumour must be provided for all patients for the Central Laboratory's ErbB2 FISH tests. Patients will remain on the study based on local ErbB2 expression results.2 If the archived tumour is not available, a biopsy must be obtained during screening and sent to TMD laboratories for the ErbB2 FISH tests.", "The procedures used in the routine clinical management of the patient (e.g., blood count, imaging study) and obtained prior to the signing of informed consent may be used for screening or reference, provided these procedures are performed in accordance with the protocol.", "Note: Informed consent may be obtained prior to the protocol selection window (i.e., from day -14 to day -1).", "In Tunisia, patients must be 20 years of age to be eligible for this study.", "Adequate function of the organ as defined below:", "System (Laboratory values)", "Hemoglobin1( 9 g/dL)Platelets( 100 X 10^9/L)International Standard Ratio (INR)( 1.2 X upper limit of normal (ULN))Thromboplastin partial time (PTT)( 1.2 X ULN)", "Hepatic:Total Bilirubine2 (1.5 X upper limit of normal (ULN))AST and ALT(2.5 X LSN)", "Renal: Serum creatinine (1.5 mg/dL) or, if serum creatinine is greater than 1.5 mg/dL,", "Calculation of creatinine clearance( 50 mL/min)", "urinary protein levels compared to creatinine(<1)", "Patients may not have had a transfusion within 7 days of the screening assessment.", "Exception: Patients with high levels of bilirubin due to Gilberts syndrome are eligible.", "\u2022 MUGA tests will be accepted in cases where an echocardiogram cannot be performed or is inconclusive or where MUGA tests are the accepted standard. Patients with a known history of uncontrolled or symptomatic angina, arrhythmia or congestive heart failure are not eligible.", "The Eastern Cooperative Oncology Group (ECOG) achieved a yield of 0-2.", "A woman is eligible to participate in this study if she is:", "- Non-child potential (i.e. physiologically unable to become pregnant), including any woman who has:", "A hysterectomy", "A bilateral oophorectomy (ovariectomy)", "A bilateral tubular ligature", "Is postmenopausal", "Patients who do not use hormone replacement therapy (HRT) should have been completely stopped for 1 year and over the age of 45, OR, in questionable cases, have a stimulating follicular hormone (FSH) value >40 mIU/mL and an estradiol value <40pg/mL (<140 pmol/L).", "For most forms of HRT, at least 2 to 4 weeks should elapse between stopping HRT and determining the menopausal state; the duration of this interval depends on the type and dosage of HRT. If a patient is determined not to be menopausal, she should use adequate contraception, as defined immediately below.", "The acceptable contraceptive methods of GSK, when used consistently and in accordance with the product label and the physician's instructions, are as follows:", "An intrauterine device with a documented failure rate of less than 1 per cent per year.", "The Vasectomized partner who is sterile before the patient enters and who is the only sexual partner for this woman.", "To complete abstinence from sexual intercourse for 14 days prior to exposure to the test product, during the dosing period and for at least 21 days after the last dose of the test product.", "\u2022 Double-bar contraception (condom with spermicide jelly, foam suppository or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).", "Note: Oral contraceptives are unreliable due to potential drug interactions.", "Patients who are breast-feeding should stop breast-feeding prior to the first dose of the test product and refrain from breast-feeding throughout treatment and for 14 days after the last dose of the test product.", "In France, a patient can only be included in this study if he or she is affiliated with or receiving a category of social security.", "- Exclusion criteria:", "Patients who meet one of the following criteria should not be included in the study:", "In the case of patients receiving HL-RH prior to the study, treatment within 14 days prior to randomization with cancer therapy (tumor embolization, chemotherapy, immunotherapy, biological or hormonal therapy) or treatment with mitomycin within 6 weeks prior to randomization cannot be resumed or started after entry into the study. Note: Patients receiving HL-RH-like therapy prior to the study may continue to receive HL-RH analogues during the duration of the study.", "Any continuing toxicity of a previous anticancer treatment that is in the first year and/or progresses in severity (with the exception of alopecia).", "\u2022 Prior treatment with lapatinib or other treatment with Her2/ErbB2 (with the exception of trastuzumab).", "Previous treatment with anti-VEGF antibodies or other targeted VEGF/VEGF-R treatment.", "The use of an experimental agent, including an experimental anticancer agent, within 28 days or 5 half-lives, whichever is longer, before the first dose of the test product.", "The use of any medicinal product is prohibited within the time limits set out in section 8.1.3.", "History of another malignancy.", "Note: Subjects who have had another malignancy and have been free of disease for 5 years, or subjects with a history of completely resected non-melanoma skin carcinoma or successfully treated in situ carcinoma, are eligible. If the subject had ever had breast cancer, it must have been HER2+ with 3+ overexpression by IHC or HER2 gene amplification unequivocally by FISH or CISH.", "The history or clinical evidence of central nervous system (CNS) metastases or leptomenic carcinomatosis, with the exception of individuals who have previously treated CNS metastases, is asymptomatic and did not require steroids or anti-seminar drugs during the two months preceding the first dose of the drug under study.", "Clinically significant gastrointestinal abnormalities that may increase the risk of GI bleeding, including, but not limited to:", "An active peptic ulcer disease", "- Intraluminal metastatic lesion/s known with suspected bleeding", "Inflammatory intestinal disorders", "- Ulcerous colitis, or other gastrointestinal disorders with an increased risk of perforation", "\u2022 History of abdominal fistula, gastrointestinal perforation or intra-abscess within 28 days prior to initiation of study therapy.", "Clinically significant gastrointestinal abnormalities that may affect the absorption of the test product, including, but limited to:", "Malabsorption syndrome", "\u2022 Major resection of the stomach or small intestine.", "Presence of uncontrolled infection.", "- Extension of the corrected QT interval (QTc) > 480 msecs.", "\u2022 History of one or more of the following cardiovascular diseases in the last 6 months:", "Angioplasty or cardiac stentation", "Myocardial infarction", "A unstable angina", "arterial thrombosis", "A symptomatic peripheral vascular disease", "- Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) (see description in Appendix 9 of Section 15.9).", "Inadequately controlled hypertension (defined as 140mmHg systolic blood pressure (SBP) or 90mmHg diastolic blood pressure (DBP).", "Note: The initiation or adjustment of an antihypertensive drug is allowed during the screening period to control a patient's BP prior to randomization. Blood pressure should be re-evaluated twice and separated by at least 1 hour. The mean SBP/DBP values for each blood pressure assessment must be < 140/90mmHg for a patient to be eligible for the study.", "\u2022 History of stroke including TIA, pulmonary embolism or deep venous thrombosis (DVT).", "\u2022 Prior surgery or major trauma within 28 days prior to the first dose of the test product and/or the presence of any unhealing injury, fracture or ulcer (other than ulcers due to inflammatory breast cancer).", "Evidence of active bleeding or haemorrhagic diathesis.", "- Haemoptysis within 6 weeks prior to the first dose of the test product.", "Known endobronchial lesions or the involvement of large pulmonary vessels by the tumor.", "Any medical, psychiatric or other serious and/or unstable condition that may affect the patient's safety, the provision of informed consent or compliance with study procedures.", "Known as immediate or delayed hypersensitivity reactions or idiosyncrasia to medicinal products chemically related to pazopanib or lapatinib.", "\u2022 Have current active liver or biliary disease (except for Gilbert's syndrome patients, asymptomatic gallstones, liver metastases or stable chronic liver disease by assessment of the investigator)."], "Results": ["Performance measures:", "Number of participants with an overall response (OR), defined as participants with a complete (CR) or partial (PR) response, assessed by response Assessment Criteria for Solid Tumours (RECIST) Version 1.0 and skin lesions", "The evaluation of the RECIST-based response was conducted at weeks 4 and 8 and every 8 weeks thereafter. The assessment of skin disease was conducted at weeks 4 and every 4 weeks thereafter. The evaluation was evaluated when the skin and RECIST assessments coincided. By RECIST, CR is the elimination of all target and non-target lesions; PR is at least a 30 percent decrease in the sum of the longest diameter (LD) of the target lesions, taking as a reference the base sum of the LD. Skin disease contained an unmeasurable and measurable skin disease, which was evaluated by skin assessment tools.", "Timeline: Baseline until disease progression or recurrence is documented, evaluated for up to 66 weeks", "Results 1:", "Category of arm/group: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo", "Arm/group description: Participants received an oral lapatinib of 1500 milligrams (mg) (6 250 mg tablets) in combination with placebo (pazopanib pairing; 2 tablets) once daily (QD).", "Total number of participants analysed: 38", "Type of measurement: Number", "Unit of measurement: participants 11", "Results 2:", "Category of arm/group: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg", "In combination with pazopanib 800 mg (2 tablets of 400 mg) QD, participants received an oral lapatinib of 1500 mg (6 tablets of 250 mg) in combination with pazopanib 800 mg (2 tablets of 400 mg) QD.", "Total number of participants analysed: 38", "Type of measurement: Number", "Unit of measurement: participants 17"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/38 (15.79 per cent)", "Neutropenia 1/38 (2.63 %)", "Sinus tachycardia 0/38 (0.00 %)", "Bradycardia 0/38 (0.00 %)", "Cardiopulmonary failure 0/38 (0.00 %)", "1/38 (2.63 per cent)", "Diarrhoea 0/38 (0.00 %)", "Nausea 1/38 (2.63 per cent)", "Abdominal pain 0/38 (0.00 %)", "Pancreatitis 0/38 (0.00 %)", "- Sudden death 1/38 (2.63 per cent)", "- Fatigue 0/38 (0.00 %)", "Asthenia 0/38 (0.00 %)", "Hepatotoxicity 0/38 (0.00 %)", "Adverse Events 2:", "Total: 14/38 (36.84 per cent)", "Neutropenia 1/38 (2.63 %)", "Sinus tachycardia 0/38 (0.00 %)", "Bradycardia 0/38 (0.00 %)", "Cardiopulmonary failure 0/38 (0.00 %)", "- Vomiting 2/38 (5.26 per cent)", "Diarrhoea 2/38 (5.26 per cent)", "- Nausea 0/38 (0.00 %)", "Abdominal pain 0/38 (0.00 %)", "Pancreatitis 0/38 (0.00 %)", "- Sudden death 1/38 (2.63 per cent)", "- Fatigue 0/38 (0.00 %)", "Asthenia 0/38 (0.00 %)", "Hepatotoxicity 1/38 (2.63%)"]}